Monday, 24 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
09 Aug 2016 Social In Japan, persistence on biologics highest in biologic-naïve (>95%) and older Pts & lowest w/ more comorbidities. https://t.co/4VTDOCpZeJ
01 Oct 2018 Social Hear nine experts talk about biosimilars in Therapeutic Update: Biosimilars, a video series brought to viewers by Sandoz. Now available on RheumNow. https://t.co/xyqelyCd2r #sponsored #biosimilars
12 Jul 2018 Social RT @ByJonGardner: Some interesting insight on why US biosimilar uptake has been so anaemic from a Leerink note. Main reasons: PBMS lose mon…
05 Dec 2017 Social FDA listing of currently approved BIOSIMILARS and their product info. 5 of 8 are for rheumatology, think you know them? https://t.co/5dQ0PI9klE
08 Aug 2017 Social Tanezumab (MAb against nerve growth factor) is being fast-tracked by FDA as a non-opioid pain reliever. https://t.co/ZXJnS7CmE4
28 Sep 2016 Social Yale study of Alopecia (areata or universalis) showed 32% of 66pts improved with tofacitinib 5mg bid after 3 months. https://t.co/DBmnWEujiM
25 Oct 2018 Social RT @WIRheum: Canabinoids in vitro CB2 receptor drives inflammation Set the stage for discovery/development of future antagonists? Danger…
29 Jul 2019 Social Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY
04 Apr 2017 Social FDA grants "breakthrough status" (expedited review) for Rituximab in Pemphigus Vulgaris based on recent Lancet study https://t.co/c7JpzzmvgM
25 Jun 2015 Social Antecdotal reports of tofacitinib success in resolving depigmentation of vitiligo. http://t.co/SuxoawAbma
22 Feb 2018 Social https://t.co/ru9Ej9aMDu of Derm mtg in San Diego has several new biologic therapies of Atopic Dermatitis, including baricitinib, upadacitinib, ASN002 (JAK/SYK inhibitor) and anti IL-33 (ANB020). https://t.co/cOm6jcPRCq
17 Nov 2016 Social RT @DrAiLynTan: Great slide on comparing biologic therapy in #rheumatoidarthritis v #Crohns v #ulcerativecolitis via @JoseCamposMD #ACR16 h…
11 Oct 2017 Social Multicenter study of135 JIA pts who stopped biologic - 76% flared; more if W/D tried before 2 years of remission. https://t.co/Fn0YXPUGkO
03 Apr 2016 Social IMS Health estimates $92 billion in global sales of branded drugs & biological products will have lost patent protection between 2011 & 2015
28 Nov 2019 Social RT @RheumNow: Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activ…
01 May 2017 Social OPT 1&2 RCT show Tofacitinib to improve nail psoriasis: NAPSI75 scores PBO 6.8%, Tofa 5mg 16.9%, 10 mg 28.1% bid https://t.co/YCtVbkF5Cf
01 Sep 2015 Social Is there a role for IVIG management? Infx or biologic contraindicated pts, vasculitis, Stills, rhupus, overlap? http://t.co/dKtEbGEiTW
06 Jun 2018 Social The FDA has a new Video Series on Biosimilars https://t.co/7BXdztDta5 - The Promise: new options, $ competition - The Basics: key terms & concepts - Interchangeability: defining the standard - The Development: abbreviated licensure path - The Data: analytics & approval process
06 Nov 2017 Social RT @regeneron: In rheumatoid #arthritis, chronically elevated IL-6 levels may drive inflammation & joint destruction. #ACR17 https://t.co/h…
23 Apr 2019 Social CORRONA study of 880 RA pts w/ hx of Solid cancer shows many on biologics following Dx. 42% were on biologics/tsDMARDs in the 12 mo before cancer. Post CA 31% were on same Rx, 5% switched biologics &10% started a biologic, the majority starting TNFi (54%). https://t.co/PjjQvFVnsI